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The fungal-derived bicyclo[2.2.2]diazaoctane alkaloids are of significant interest to the 
scientific community for their potent and varied biological activities. Within this large 
and diverse family of natural products the insecticidal metabolite (+)-brevianamide A is 
particularly noteworthy for its synthetic intractability and inexplicable biogenesis. 
Despite five decades of research, this alkaloid has never succumbed to chemical 
synthesis due to insurmountable issues of reactivity and selectivity associated with all 
previously explored strategies. We herein report the first chemical synthesis of 
(+)-brevianamide A (7 steps, 7.2% overall yield, 750 mg scale), which includes a 
bio-inspired cascade transformation of the linearly fused (−)-dehydrobrevianamide E 
into the topologically complex bridged-spiro-fused structure of (+)-brevianamide A. 
 
The Diels–Alder cycloaddition is one of the most important reactions in synthetic 
organic chemistry, allowing the stereoselective construction of six-membered rings through 
the concerted formation of two new bonds (Figure 1a).1 The limited appearance of Diels–
Alder reactions in biosynthetic pathways has always fascinated chemists.2-6 The 
bicyclo[2.2.2]diazaoctane alkaloids, which are a vast group of natural products isolated from 
various marine and terrestrial fungi, have played a key role in the development of our 
understanding of biosynthetic Diels–Alder reactions.7,8 They are also of broader interest to 
both chemists and biologists alike due to their important biological activities, diverse 
biosynthetic origins, and synthetically daunting structures. There are two distinct families of 
bicyclo[2.2.2]diazaoctane alkaloids, the monooxopiperazine-type structures (Figure 1b), 
which include the anthelmintic paraherquamides,9-11 calmodulin-inhibiting 
malbrancheamides,12 and neuroprotective chrysogenamides;13 and the dioxopiperazine-type 
structures (Figure 1c), which include the cytotoxic stephacidins and notoamides,14,15 and the 
insecticidal brevianamides.16,17 
Brevianamides A (1) and B (2) were originally isolated by Birch and Wright in 1969 
from the fungus Penicillium brevicompactum,16 and were the first known 
bicyclo[2.2.2]diazaoctane alkaloids (Figure 1c).7,8 Brevianamide A (1) exhibits potent 
antifeedant activity against the larvae of the insect pests Spodoptera frugiperda (fall 
armyworm) and Heliothis virescens (tobacco budworm),17 and is the major isolated 
diastereomer (ratio of A to B ≳90:10).18,19 In 1970, Porter and Sammes proposed that the 
bicyclo[2.2.2]diazaoctane cores of brevianamides A (1) and B (2) could be biosynthesised 
through an intramolecular hetero-Diels–Alder cycloaddition (Figure 1d),20 a proposal which 
has been extended to encompass all bicyclo[2.2.2]diazaoctane alkaloids.7,8 Recently, Diels–
Alderase enzymes have been identified in the biosynthetic gene clusters responsible for the 
malbrancheamide and paraherquamide monooxopiperazine-type alkaloids.21 However, no 
Diels–Alderase enzyme has yet been identified for the brevianamides, nor any other 
dioxopiperazine-type alkaloid.22,23 Furthermore, despite five decades of research, no chemical 
synthesis of brevianamide A (1) has been achieved, yet several syntheses of the minor 
diastereomer, brevianamide B (2), have been reported (for a full summary, see 
Supplementary Information, Section 1).24-32 Despite the similar structures of the two natural 
products, none of these strategies have been successfully applied to the synthesis of 
brevianamide A (1) due to insurmountable issues of reactivity and selectivity. 
Following decades of detailed chemical and biochemical studies, the biosynthetic 
origins of (+)-brevianamide A (1) and B (2) still remain unknown. We herein propose a 
modified biosynthetic hypothesis, which builds upon the pioneering work of several research 
groups.7,8 To appreciate the origins of this modified biosynthetic proposal it is important to 
first outline key details of the elegant work of Williams and co-workers.26-29 Their 
biomimetic synthetic studies have mainly focused upon an early proposed pathway (Figure 2, 
Pathway 1),33 which was informed by the seminal work of Birch and Sammes.20,34-36 The 
pathway begins with a stereoablative oxidation of (+)-deoxybrevianamide E (3) to give 
achiral azadiene 4, which then undergoes enantioselective Diels–Alder cycloaddition to give 
a scalemic mixture of bicyclo[2.2.2]diazaoctane enantiomers, 5 and ent-5. Both enantiomers 
then undergo (R)-selective indole oxidation and a [1,2]-alkyl shift, so that the major 
enantiomer (5) gives brevianamide A (1) and the minor enantiomer (ent-5) gives 
brevianamide B (2). Williams’ synthetic studies, however, revealed that this proposed Diels–
Alder reaction (4 to 5/ent-5) actually produces an unwanted diastereomer as the major 
product.29 Furthermore, biosynthetic feeding experiments with isotopically labelled 5 failed 
to show any significant incorporation into (+)-brevianamide A (1).37 Williams, therefore, 
proposed an alternative biosynthetic pathway (Figure 2, Pathway 2), which begins with a 
diastereoselective indole oxidation of (+)-deoxybrevianamide E (3) to give 
hydroxyindolenine 6.37,38 A stereospecific [1,2]-alkyl shift then gives indoxyl 7, which 
undergoes a diketopiperazine oxidation and Diels–Alder cycloaddition to give brevianamides 
A (1) and B (2).37,38 Williams and co-workers reasoned that “[t]he preponderance of 1 over 2 
would be due either to the relative activities of two different [Diels–Alderase] enzymes or the 
affinity of a single enzyme active site for the individual conformers”.37 All efforts to 
substantiate this second-generation pathway in vitro, however, have failed, largely due to the 
instability of indoxyl 7.7 Furthermore, hydroxyindolenine 6 is likely to undergo rapid 5-exo-
trig cyclisation to give the known shunt-metabolite brevianamide E (8),16,34 which is 
proposed to be a biosynthetic dead-end.37 
Our modified biosynthetic hypothesis for (+)-brevianamide A (1) involves an 
alternative biosynthetic precursor, (+)-dehydrodeoxybrevianamide E (9), which is a known 
natural product isolated from various Penicillium and Aspergillus species (Figure 3).39-41 
Crucially, the diketopiperazine ring in (+)-dehydrodeoxybrevianamide E (9) is already at the 
oxidation level required for a later Diels–Alder reaction. Our pathway involves a point-to-
point chirality transfer via a sequential diastereoselective indole oxidation, stereospecific 
[1,2]-alkyl shift, and tautomerisation, to give enantiopure azadiene 10. Diels–Alder 
cycloaddition of azadiene 10 would then give brevianamides A (1) and B (2).37,38 Although 
our proposed intermediate 11 is likely to undergo reversible 5-exo-trig cyclisation to give 
pentacycle 12, this is not a known natural product and is therefore unlikely to represent a 
dead-end (cf. brevianamide E (8) in Pathway 2, Figure 2). We herein report the first total 
synthesis of brevianamide A (1), following a strategy inspired by our modified biosynthetic 
proposal. 
 
Results and Discussion 
The synthesis of (+)-dehydrodeoxybrevianamide E (9) commenced with phthaloyl protection 
of commercially available L-tryptophan methyl ester 13 (Figure 4).42 The crude product from 
this reaction, ester 14, was subjected directly to Danishefsky’s reverse prenylation conditions 
using B-prenyl-9-BBN to give intermediate 15 in 69% yield over the two steps.43 Hydrolysis 
of methyl ester 15 was accompanied by ring opening of the phthaloyl group to give diacid 16, 
which presumably explains why a protecting group switch from phthaloyl to 
tert-butyloxycarbonyl or trityl has been undertaken in related synthetic endeavours.43,44 To 
avoid these extraneous two steps (deprotection/re-protection) we explored the possibility of 
an SN2-type demethylation of methyl ester 15. While LiI in EtOAc, as reported by Fisher and 
Trinkle,45 gave the desired product 17, we found LiCl in DMF gave a cleaner reaction. 
Lithium carboxylate 17 was then subjected to a one-pot acyl chloride formation and imine 
acylation reaction with dehydroproline 18 to give N-acyl enamine 19.46 Attempts to deprotect 
the primary amine in 19 using conventional phthaloyl deprotection reagents, such as 
hydrazine, ethylene diamine, methylamine, hydroxylamine, ethanolamine, and 
phenylhydrazine resulted in unwanted cleavage of the amide bond. Our search for less 
nucleophilic reagents eventually led us to ammonia in methanol,47 which not only 
deprotected the primary amine but also resulted in spontaneous cyclisation to give 
(+)-dehydrodeoxybrevianamide E (9) in 49% yield over the three steps from methyl ester 15. 
Thus, by developing a new imine acylation reaction and avoiding unnecessary protecting 
group manipulations, the shortest total synthesis of (+)-dehydrodeoxybrevianamide E (9) has 
been achieved, proceeding in a longest linear sequence of 5 steps, 34% overall yield, and 
requiring just two chromatographic purifications (cf. previous synthesis: 12 steps, 8% overall 
yield).29 
Oxidation of (+)-dehydrodeoxybrevianamide E (9) using a variety of oxidants (e.g., 
dioxiranes,43 oxaziridines,23 singlet oxygen,48 and peroxy acids) gave 
dehydrobrevianamide E (12), alongside diastereomer 20 (Figure 4). Use of m-CPBA gave the 
highest diastereoselectivity (d.r. 64:36, 57% yield), with no appreciable improvement 
observed at lower temperatures. The stereoselectivity of related biosynthetic indole 
oxidations is known to be controlled by flavin-dependent monooxygenase enzymes.8 
Synthetic access to both diastereomers 12 and 20, however, enabled us to prepare both the 
natural-(+) and unnatural-(−) enantiomers of brevianamides A (1) and B (2) (vide infra). 
Exposure of dehydrobrevianamide E (12) to LiOH in water at ambient temperature for 30 
minutes successfully gave (+)-brevianamide A (1) and (+)-brevianamide B (2) in a combined 
63% yield, presumably via the domino retro-5-exo-trig/[1,2]-alkyl shift/Diels–Alder reaction 
sequence outlined in Figure 3. Keeping the reaction time to a minimum and avoiding elevated 
temperatures was essential to prevent alkaline hydrolysis of the products, as previously 
observed by Birch and co-workers.34 Following purification by column chromatography, 
which is only the fourth purification in the entire seven-step synthesis, 750 milligrams of (+)-
brevianamide A (1) and 60 milligrams of (+)-brevianamide B (2) were isolated.49 Chiral-
HPLC analysis revealed both products (1 and 2) were isolated in a 93:7 enantiomeric ratio, 
which is not surprising given many of our synthetic intermediates may have undergone 
partial racemisation; recrystallisation gave (+)-brevianamide A (1) in an enantiomeric ratio of 
99:1. The unnatural (−)-enantiomers of brevianamides A (1) and B (2) were similarly 
accessed by subjecting the minor diastereomer, compound 20, to the same reaction conditions 
(Figure 4). 
The Diels–Alder reaction produces (+)-brevianamide A (1) and (+)-brevianamide B 
(2) in a 93:7 diastereomeric ratio (Figure 3), which closely matches the ratio observed when 
they are isolated from Penicillium brevicompactum (for further details, see Supplementary 
Information, Section 2).18 Thus, we suggest that this Diels–Alder reaction might be a 
spontaneous process exploited by Nature without direct enzyme participation.37 This is in 
contrast to the requirement of Diels–Alderase enzymes in the stereoselective biogenesis of 
the closely related malbrancheamide and paraherquamide alkaloids.21 During the review 
process for this manuscript, Williams, Sherman, Li and co-workers reported their 
identification of the brevianamide A biosynthetic gene cluster.50 Their detailed biosynthetic 
studies, which included targeted gene disruption, heterologous expression, precursor 
incorporation studies, and in vitro biochemical analysis also support a spontaneous, non-
enzyme mediated, biosynthetic Diels–Alder reaction.50 
In summary, 50 years after its discovery by Birch,16 the first chemical synthesis of 
brevianamide A (1) has been achieved. Key to the success of this synthesis is a bio-inspired 
one-step cascade transformation of the linearly fused pentacyclic dehydrobrevianamide E 
(12) into the far more complex hexacyclic structure of brevianamide A (1). This complexity 
generating sequence would likely not have been designed from a purely retrosynthetic 
analysis of the target, demonstrating the unique utility of the biomimetic approach in natural 
product synthesis. 
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Fig. 1 The Diels–Alder cycloaddition and representative examples of bicyclo[2.2.2]diazaoctane alkaloids, 
which are proposed to be biosynthesised via intramolecular hetero-Diels–Alder reactions. a, The Diels–
Alder cycloaddition. b, Representative monooxopiperazine-type bicyclo[2.2.2]diazaoctane alkaloids 
(bicyclo[2.2.2]diazaoctane cores highlighted in blue). c, Representative dioxopiperazine-type 
bicyclo[2.2.2]diazaoctane alkaloids (bicyclo[2.2.2]diazaoctane cores highlighted in green). d, Sammes’ 
proposed biosynthetic hetero-Diels–Alder reaction. 
 
Fig 2 Previous biosynthetic proposals for brevianamides A and B. In 1989, building on the earlier work of 
Birch and Sammes, Williams and co-workers proposed Pathway 1 as a plausible biosynthetic pathway towards 
brevianamides A and B.33 In 1993, following their synthetic and biosynthetic studies, Williams and co-workers 
proposed an alternative order of biosynthetic transformations, as shown in Pathway 2.37 Biosynthetic feeding 
experiments with isotopically labelled 5 and (−)-brevianamide E (8), however, show no significant 
incorporation into 1 or 2. 
 
Fig. 3 A modified biosynthetic proposal for brevianamides A and B. The known natural product 
(+)-dehydrodeoxybrevianamide E (9), which has the diketopiperazine ring at the oxidation level required for a 
later Diels–Alder reaction, is invoked as an alternative biosynthetic precursor towards brevianamide A and B. 
This avoids the intermediacy of indoxyl 7 (Figure 2, Pathway 2), the instability of which has thwarted previous 
biomimetic approaches. Although oxidation of (+)-dehydrodeoxybrevianamide E (9) is expected to give 
compound 12, akin to the oxidative ring closure of 3 to give 8 (Figure 2, Pathway 2), 
(−)-dehydrobrevianamide E (12) is not a known natural product and is therefore less likely to represent a 
biosynthetic dead-end. 
 
Fig. 4 Total synthesis of brevianamides A and B. The synthesis begins with the shortest reported total 
synthesis of (+)-dehydrodeoxybrevianamide E (9) (5 steps, 34% overall yield, 8.5 gram scale). Oxidation of 
(+)-dehydrodeoxybrevianamide E (9) gives a diastereomeric mixture of dehydrobrevianamide E (12) and 20. 
Exposure of 12 and 20 to LiOH in water gives the natural and unnatural enantiomers of (+)-brevianamides A (1) 
and B (2), respectively. 9-BBN, 9-borabicyclo(3.3.1)nonane; Phth, phthaloyl; DMF, dimethylformamide; NCS, 
N-chlorosuccinimide; m-CPBA, meta-chloroperoxybenzoic acid. 
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